Psychopharmacological Drugs Advisory Committee

March 9, 2000


FDA Overview of Issues, Thomas Laughren, M.D., Team Leader, Psychiatric Drug Products Group ppt html

Psychosis of Alzheimer Disease: A Distinct Syndrome, Dilip Jeste, M.D., University of San Diego ppt html

The Concept of Secondary Mania in Dementia, Pierre Tariot, M.D., Monroe Community Hospital ppt html

The Conceptualization of Behavioral and Psychological Symptoms Associated with Dementia: Issues related to the Development of Pharmacologic Interventions, Jiska Cohen-Mansfield, Ph.D., George Washington University ppt html

Classifying the Manifestations of Alzheimer’s Disease in DSM-IV-TR, Eric Caine, M.D., University of Rochester ppt html

Criteria for Psychiatric Symptoms in Alzheimer’s Disease Clinical Trials, Jeffrey Cummings, M.D., UCLA ppt html

BPSD and the Psychosis of AD: Treatment Possibilities, Barry Reisberg, MD, New York University wpd pdf

American Psychiatric Association, Cristopher Colenda, M.D., Jacob Mintzer, M.D. ppt html

Janssen Pharmaceutica, Rick Martinez, M.D., Director CNS Medical Affairs ppt html

Eli Lilly, Alan Breier, M.D., Leader Zyprexa Product Team ppt html

THE BEHAVIORAL COMMITTEE OF THE INTERNATIONAL WORKING GROUP FOR THE HARMONIZATION OF DEMENTIA DRUG GUIDELINES STATEMENT TO THE DIVISION OF NEUROPHARMACOLOGICAL DRUG PRODUCTS (DNDP) ISSUE PAPER for March 9, 2000 Meeting of the Psychopharmacological Drugs Advisory Committee Meeting on the Various Psychiatric and Behavioral Disturbances Associated with Dementia. Doc pdf